Logo image
Plasmodium vivax malaria in spite of atovaquone/proguanil (malarone) prophylaxis
Journal article   Open access   Peer reviewed

Plasmodium vivax malaria in spite of atovaquone/proguanil (malarone) prophylaxis

Laura Povinelli, Tim A Monson, Barry C Fox, Monica E Parise, Joanne M Morrisey and Akhil B Vaidya
Journal of travel medicine, v 10(6), pp 353-355
Nov 2003
PMID: 14642204
url
https://doi.org/10.2310/7060.2003.9318View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

Aged Animals Antimalarials - therapeutic use Atovaquone Cytochromes b - genetics Drug Administration Schedule Drug Combinations Ethiopia Humans Malaria, Vivax - blood Malaria, Vivax - diagnosis Malaria, Vivax - drug therapy Malaria, Vivax - prevention & control Male Naphthoquinones - therapeutic use Plasmodium vivax - genetics Polymorphism, Genetic Proguanil - therapeutic use Sequence Analysis, DNA - methods Travel Treatment Failure United States
A 70-year-old male scientist, who had returned 5 weeks earlier from Ethiopia, was admitted to the hospital with symptoms consistent with malaria. On physical examination, he had orthostatic hypotension. He was dehydrated and showed a mild clinical delirium. Abdominal examination revealed a possible spleen tip, and he had petechial lesions bilaterally below his knees. Laboratory data revealed his white blood cell count to be 4,500/mL, with 67% polymorphonuclear cells and 15% band forms. The hemoglobin level was 13.9 g/dL, and the platelet count was low, at 32,000/mL.

Metrics

6 Record Views
22 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Infectious Diseases
Public, Environmental & Occupational Health
Logo image